SCHEMBL3205314

SCHEMBL3205314

Nc1ccc(N2CCCN(C(=O)C3CCCCC3)CC2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.54
HCRTR2 O43614 1/20 0.54
GBA1 P04062 1/20 0.50
DGAT1 O75907 1/20 0.49
TSHR P16473 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAP4K4 O95819 1/20 0.47
LMNA P02545 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPK1 P28482 2/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
CNR2 P34972 2/20 0.42
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2783570 0.96 TSHR (0.51) HCRTR1HCRTR2GBA1DGAT1TSHR
SCHEMBL3216450 0.95 MAP4K4 (0.49) HCRTR1HCRTR2GBA1DGAT1ALDH1A1
SCHEMBL3665114 0.90 CKS1B (0.52) DGAT1ALDH1A1MAP4K4LMNAKMT2A
SCHEMBL3213765 0.85 HRH3 (0.55) HCRTR1HCRTR2GBA1DGAT1ALDH1A1
SCHEMBL23244261 0.82 TDP1 (0.55) HCRTR1HCRTR2GBA1DGAT1TSHR
SCHEMBL3209251 0.82 KMT2A (0.59) HCRTR1HCRTR2TSHRALDH1A1LMNA
SCHEMBL3634177 0.82 GRIN2D (0.42) ALDH1A1MAP4K4LMNAKMT2AMEN1
SCHEMBL3810634 0.81 GRIN2D (0.41) ALDH1A1MAP4K4LMNAKMT2AMEN1
SCHEMBL29593660 0.79 AKR1C3 (0.60) HCRTR1HCRTR2GBA1DGAT1TSHR
SCHEMBL24313309 0.79 AKR1C3 (0.60) HCRTR1HCRTR2GBA1DGAT1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211884-B2 2,2-Dimethyl-4-oxo-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepan-1-yl)-butyric acid, hydrochloride; obesity, type II diabetes mellitus and metabolic syndrome MADRIGAL PHARMACEUTICALS, INC. (US) 2012-07-03 US disclosed
WO-2010017040-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC (US) 2010-02-11 WO disclosed
US-20100035864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT HCRTR1 4296/4885HCRTR2 3862/4885GBA1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.